Clinical Trial Update: To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer

View source ↗

Summary

A clinical trial update describing a study to identify primary resistance to CDK4/6 inhibitors in breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• CDK4/6 inhibitors
• KISQALI (ribociclib)
• Palbociclib (palbociclib)
• VERZENIO (ABEMACICLIB)

Snippet

Sponsor: Fondazione Sandro Pitigliani | Conditions: Metastatic Breast Cancer, ER Positive Breast Cancer | Status: RECRUITING